nach oben

Heart Failure Reviews

Erschienen in:

01.05.2015

Chronic kidney disease and cardiovascular complications

verfasst von: Luca Di Lullo, Andrew House, Antonio Gorini, Alberto Santoboni, Domenico Russo, Claudio Ronco

Erschienen in: Heart Failure Reviews | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular diseases such as coronary artery disease, congestive heart failure, arrhythmias and sudden cardiac death represent main causes of morbidity and mortality in patients with chronic kidney disease (CKD). Pathogenesis includes close linkage between heart and kidneys and involves traditional and non-traditional cardiovascular risk factors. According to a well-established classification of cardiorenal syndrome, cardiovascular involvement in CKD is known as “type-4 cardiorenal syndrome” (chronic renocardiac). The following review makes an overview about epidemiology, pathophysiology, diagnosis and treatment of cardiovascular complications in CKD patients.

Ronco C (2011) The cardiorenal syndrome: basis and common ground for a multidisciplinary patient-oriented therapy. Cardiorenal Med 1:3–4

Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, ADHERE Scientific Advisory Committee and Investigators (2007) High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13(6):422–430PubMedCrossRef

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1995) The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5(12):2024–2031PubMed

Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS (1995) Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47(3):884–890PubMedCrossRef

Selby NM, Kolhe NV, McIntyre CW et al (2012) Defining the cause of death in hospitalized patients with acute kidney injury. PLoS One 7(11):e48580PubMedCentralPubMedCrossRef

Garg AX, Clark WF, Haynes RB, House AA (2002) Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 61(4):1486–1494PubMedCrossRef

US Renal Data System (2012) USRDS 2012 Annual data report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD

Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17(7):2034–2047PubMedCrossRef

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305PubMedCrossRef

10.

US Renal Data System (2009) USRDS 2009 Annual data report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD

11.

Shastri S, Sarnak MJ (2010) Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis 56(2):399–417PubMedCrossRef

12.

Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, Brown WW, Burrows NR, Jurkovitz CT, McFarlane SI, Norris KC, Shlipak M, Whaley-Connell AT, Chen SC, Bakris GL, McCullough PA (2010) Prevalence of CKD and comorbid illness in elderly patients in the united states: results from the kidney early evaluation program (KEEP). Am J Kidney Dis 55(3 Suppl 2):S23–S33PubMedCrossRef

13.

Bansal N, Keane M, Delafontaine P, Dries D, Foster E, Gadegbeku CA, Go AS, Hamm LL, Kusek JW, Ojo AO, Rahman M, Tao K, Wright JT, Xie D, Hsu CY, CRIC Study Investigators (2013) A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study. Clin J Am Soc Nephrol 8(3):355–362PubMedCentralPubMedCrossRef

14.

Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J (2007) Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 18(4):1307–1315PubMedCrossRef

15.

Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, Astor BC (2012) Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis 60(2):207–216PubMedCentralPubMedCrossRef

16.

Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN (2013) Meta-analysis global group in chronic heart failure (MAGGIC). Predicting survival in heart failure: a risk score based on 39,372 patients from 30 studies. Eur Heart J 34(19):1404–1413PubMedCrossRef

17.

Levin A, Singer J, Thompson CR, Ross H, Lewis M (1996) Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27(3):347–354PubMedCrossRef

18.

Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, Barre PE (1990) The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 55(2):114–120PubMedCrossRef

19.

Lezaic V, Tirmenstajn-Jankovic B, Bukvic D, Vujisic B, Perovic M, Novakovic N, Dopsaj V, Maric I, Djukanovic L (2009) Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification. Clin Nephrol 71(1):21–29PubMedCrossRef

20.

Di Lullo L, Floccari F, Santoboni A, Barbera V, Rivera RF, Granata A, Morrone L, Russo D (2013) Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol 26(4):739–744PubMedCrossRef

21.

Olgaard K, Lewin E, Silver J (2011) Calcimimetics, vitamin D and ADVANCE in the management of CKD–MBD. Nephrol Dial Transplant 26(4):1117–1119

22.

MacRae JM, Pandeya S, Humen DP, Krivitski N, Lindsay RM (2004) Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am J Kidney Dis 43(5):e17–e22PubMedCrossRef

23.

Di Lullo L, Floccari F, Polito P (2011) Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clin Pract 118:c258–c262CrossRef

24.

Fort J (2005) Chronic renal failure: a cardiovascular risk factor. Kidney Int 68(Suppl 99):S25–S29

25.

Schiffrin EL, Lipman ML, Mann JF (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116(1):85–97PubMedCrossRef

26.

Bologa RM, Levine DM, Parker TS et al (1998) Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32(1):107–114PubMedCrossRef

27.

Parikh SV, de Lemos JA (2006) Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci 332(4):186–197PubMedCrossRef

28.

Austin WJ, Bhalla V, Hernandez-Arce I et al (2006) Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 126(4):506–512PubMedCrossRef

29.

Ronco C, Di Lullo L (2014) Cardiorenal syndrome. Heart Fail Clin 10(2):251–280PubMedCrossRef

30.

Maisel AS, Katz N, Hillege HL et al (2011) Biomarkers in kidney and heart disease. Nephrol Dial Transplant 26(1):62–74PubMedCrossRef

31.

Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(5 Suppl 3):S112–S119PubMedCrossRef

32.

Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM (1984) Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 55(5):669–675PubMedCrossRef

33.

Entin-Meer M, Ben-Shoshan J, Maysel-Auslender S, Levy R, Goryainov P, Schwartz I, Barshack I, Avivi C, Sharir R, Keren G (2012) Accelerated renal fibrosis in cardiorenal syndrome is associated with long-term increase in urine neutrophil gelatinase-associated lipocalin levels. Am J Nephrol 36(2):190–200PubMedCrossRef

34.

Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ, Krum H (2012) Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. Am J Physiol Heart Circ Physiol 302(9):H1884–H1893PubMedCrossRef

35.

Jovanovich A, Ix JH, Gottdiener J, McFann K, Katz R, Kestenbaum B, de Boer IH, Sarnak M, Shlipak MG, Mukamal KJ, Siscovick D, Chonchol M (2013) Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 231(1):114–119PubMedCrossRef

36.

Shamseddin MK, Parfrey PS, Medscape (2011) Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 7(3):145–154

37.

Kajstura J, Cigola E, Malhotra A et al (1997) Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29(3):859–870PubMedCrossRef

38.

Kingma JG Jr, Vincent C, Rouleau JR, Kingma I (2006) Influence of acute renal failure on coronary vasoregulation in dogs. J Am Soc Nephrol 17(5):1316–1324PubMedCrossRef

39.

Lok DJ, Lok SI, Bruggink-André de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102(2):103–110PubMedCrossRef

40.

Chan CT, Levin NW, Chertow GM et al (2010) Determinants of cardiac autonomic dysfunction in ESRD. Clin J Am Soc Nephrol 5(10):1821–1827PubMedCentralPubMedCrossRef

41.

Winkelmayer WC, Patrick AR, Liu J et al (2011) The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22(2):349–357PubMedCentralPubMedCrossRef

42.

Baber U, Howard VJ, Halperin JL et al (2011) Association of chronic kidney disease with atrial fibrillation among adults in the United States: reasons for geographic and racial differences in stroke (REGARDS) study. Circ Arrhythm Electrophysiol 4(1):26–32PubMedCentralPubMedCrossRef

43.

Soliman EZ, Prineas RJ, Go AS et al (2010) Chronic kidney disease and prevalent atrial fibrillation: the chronic renal insufficiency cohort (CRIC). Am Heart J 159(6):1102–1107PubMedCentralPubMedCrossRef

44.

Boerrigter G, Costello-Boerrigter LC, Abraham WT, Sutton MG, Heublein DM, Kruger KM, Hill MR, McCullough PA, Burnett JC Jr (2008) Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail 14(7):539–546PubMedCentralPubMedCrossRef

45.

Cai Q, Mukku VK, Ahmad M (2013) Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev 9(4):331–339PubMedCentralPubMedCrossRef

46.

Wang LW, Fahim MA, Hayen A, Mitchell RL, Lord SW, Baines LA, Craig JC, Webster AC (2011) Cardiac testing for coronary artery disease in potential kidney transplant recipients: a systematic review of test accuracy studies. Am J Kidney Dis 57(3):476–487PubMedCrossRef

47.

Chonchol M, Whittle J, Desbien A, Orner MB, Petersen LA, Kressin NR (2008) Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol 28(2):354–360PubMedCrossRef

48.

Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD (2003) Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63(3):793–808PubMedCrossRef

49.

Cheung AK, Sarnak MJ, Yan G et al (2000) Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58(1):353–362PubMedCrossRef

50.

Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces it into the uremic puzzle? Clin J Am Soc Nephrol 3(2):505–521PubMedCrossRef

51.

Moe SM, Chen NX (2008) Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19(2):213–216PubMedCrossRef

52.

Shioi A, Taniwaki H, Jono S et al (2001) Monckeberg’s medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis 38(supplement 1):S7–S9

53.

Shanahan CM, Cary NRB, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME (1999) Medial localization of mineralization-regulating proteins in association with Monckeberg’s sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 100(21):2168–2176PubMedCrossRef

54.

Stenvinkel P, Chung SH, Heimbürger O, Lindholm B (2001) Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 21(supplement 3):S157–S162

55.

London GM, Guerin AP, Marchais SJ, Metivier, Pannier FB, Adda H (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18(9):1731–1740

56.

Caliskan Y, Demirturk M, Ozkok A et al (2010) Coronary artery calcification and coronary low velocity in haemodialysis patients. Nephrol Dial Transplant 25(8):2685–2690PubMedCrossRef

57.

Van Der Velde M, Matsushita K, Coresh J et al (2011) Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: a collaborative meta-analysis of high-risk population cohorts. Kidney Int 79(12):1341–1352

58.

Shirani J, Berezowski K, Roberts WC (1995) Quantitative measurement of normal and excessive (cor adiposum) subepicardial adipose tissue, its clinical significance, and its effect on electrocardiographic QRS voltage. Am J Cardiol 76(5):1–19CrossRef

59.

Di Lullo L, Floccari F, Granata A, D’Amelio A, Rivera R, Fiorini F, Malaguti M, Timio M (2011) Ultrasonography: Ariadne’s thread in the diagnosis of cardiorenal syndrome. Cardiorenal Med 2(1):11–17

60.

Di Lullo L, Floccari F, Rivera R, Barbera V, Granata A, Otranto G, Mudoni A, Malaguti M, Santoboni A, Ronco C (2013) Pulmonary hypertension and right heart failure in chronic kidney disease: new challenge for 21st-century cardionephrologists. Cardiorenal Med 3:96–103

61.

Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP (2014) Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. JACC Cardiovasc Image 7(7):703–714

62.

Stewart GA, Foster J, Cowan M et al (1999) Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 56:2248–2253PubMedCrossRef

63.

Silberberg JS, Barre PE, Prichard SS, Sniderman AD (1989) Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286–290PubMedCrossRef

64.

Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE (1996) Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11:1277–1285PubMedCrossRef

65.

Ritz E, Bommer J (2009) Cardiovascular problems on hemodialysis: current deficits and potential improvement. Clin J Am Soc Nephrol 4:S71–S78PubMedCrossRef

66.

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr 18:1440–1463PubMedCrossRef

67.

Takeuchi M, Nishikage T, Mor-Avi V, Sugeng L, Weinert L, Nakai H, Salgo IS, Gerard O, Lang RM (2008) Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. J Am Soc Echocardiogr 21:1001–1005PubMedCrossRef

68.

Pewsner D, Juni P, Egger M, Battaglia M, Sundstrom J, Bachmann LM (2007) Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ 335:711PubMedCentralPubMedCrossRef

69.

Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R (2009) Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 53:1621–1628PubMedCrossRef

70.

Karohl C, D’Marco Gascón L, Raggi P (2011) Noninvasive imaging for assessment of calcification in chronic kidney disease. Nat Rev Nephrol 7(10):567–577PubMedCrossRef

71.

Desbien AM, Chonchol M, Gnahn H, Sander D (2008) Kidney function and progression of carotid intima-media thickness in a community study Am J Kidney Dis 51(4):584–593

72.

Salk I, Yildiz G, Egilmez H, Atalar MH, Candan F, Cetin A (2014) Carotid artery Doppler ultrasonography in patients with chronic kidney disease. Med Sci Monit 7(20):11–17

73.

Briet M, Bozec E, Laurent S et al (2006) Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 69:350–357PubMedCrossRef

74.

Chue CD, Edwards NC, Ferro CJ, Townend JN, Steeds RP (2013) Effects of age and chronic kidney disease on regional aortic distensibility: a cardiovascular magnetic resonance study. Int J Cardiol 168:4249–4254PubMedCrossRef

75.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869PubMedCrossRef

76.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860PubMedCrossRef

77.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group (2003) Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138(7):542–549PubMedCrossRef

78.

Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P (2006) Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70(7):1318–1324PubMedCrossRef

79.

Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C (2013) Interaction between baseline and early worsening of renal function and efficacy of renin–angiotensin–aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. Eur J Heart Fail 15(11):1236–1244PubMedCrossRef

80.

Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R (2003) Carvedilol increases 2-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41(9):1438–1444PubMedCrossRef

81.

Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, Bohm M, Coats AJ, Roughton M, Poole-Wilson P, Tavazzi L, Flather M, SENIORS Investigators (2009) Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 11(9):872–880PubMedCentralPubMedCrossRef

82.

The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med 316(23):1429–1435

83.

Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72(9):1130–1137

84.

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367(26):2482–2494

85.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, TNT (Treating to New Targets) Investigators (2008) Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (treating to new targets) study. J Am Coll Cardiol 51(15):1448–1454PubMedCrossRef

86.

Wanner C, Krane V, Marz W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238–248PubMedCrossRef

87.

Fellstrom BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360(14):1395–1407PubMedCrossRef

88.

Suzuki H, Watanabe Y, Kumagai H, Shuto H (2013) Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Ther Adv Cardiovasc Dis 7(6):306–315PubMedCrossRef

89.

FHN Trial Group, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS (2010) In-center hemodialysis six times per week versus three times per week. N Engl J Med 363(24):2287–2300

90.

Matsumoto M, Io H, Furukawa M, Okumura K, Masuda A, Seto T, Takagi M, Sato M, Nagahama L, Omote K, Hisada A, Horikoshi S, Tomino Y (2012) Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography. J Nephrol 25(5):794–801PubMedCrossRef

91.

Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J (2005) Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46(5):799–811PubMedCrossRef

92.

Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P (2009) Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 4(4):755–762PubMedCentralPubMedCrossRef

93.

Di Lullo L, Floccari F, Granata A, Malaguti M (2012) Low-dose treatment with erythropoiesis-stimulating agents and cardiovascular Geometry in chronic kidney disease: is darbepoetin-α more effective than expected? Cardiorenal Med 2:18–25

94.

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355(20):2085–2098PubMedCrossRef

95.

Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355(20):2071–2084PubMedCrossRef

96.

Besarab A, Goodkin DA, Nissenson AR, Normal Hematocrit Cardiac Trial Authors (2008) The normal hematocrit study: follow-up. N Engl J Med 358(4):433–434PubMedCrossRef

97.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019–2032PubMedCrossRef

98.

Kidney Disease Outcomes Quality Initiatives (K/DOQI) (2004) Clinical practice guidelines on hypertension and hypertensive agents in chronic kidney disease. Am J Kidney Dis 43(5 Suppl 1):S1–S290

99.

Kidney Disease Outcomes Quality Initiatives (K/DOQI) (2007) Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49(2 Suppl 2):S12–S154

100.

Kidney Disease Outcomes Quality Initiatives (K/DOQI) (2009) Clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int 76(Suppl 113):S50–S69

101.

Di Lullo L, Santoboni A, Floccari F, Rivera R, De Pascalis A, Gorini A, Barbera V, Ronco C (2014) Chronic kidney disease and sudden death. G Ital Nefrol 31(3)

102.

Herzog CA, Mangrum JM, Passman R (2008) Sudden cardiac death and dialysis patients. Semin Dial 21(4):300–307PubMedCrossRef

Titel: Chronic kidney disease and cardiovascular complications
verfasst von: Luca Di Lullo
Andrew House
Antonio Gorini
Alberto Santoboni
Domenico Russo
Claudio Ronco
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 3/2015
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-014-9460-9

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

RV diastolic dysfunction: time to re-evaluate its importance in heart failure

Evidence of clinical efficacy of counterpulsation therapy methods

Exosome and its roles in cardiovascular diseases

Hospital readmission in heart failure, a novel analysis of a longstanding problem